Annual CFO
-$1.30 M
-$1.85 M-335.88%
December 31, 2023
Summary
- As of February 7, 2025, BGLC annual cash flow from operations is -$1.30 million, with the most recent change of -$1.85 million (-335.88%) on December 31, 2023.
- During the last 3 years, BGLC annual CFO has fallen by -$1.85 million (-335.50%).
- BGLC annual CFO is now -335.50% below its all-time high of $552.70 thousand, reached on December 1, 2020.
Performance
BGLC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.46 M
-$789.00 K-117.67%
September 30, 2024
Summary
- As of February 7, 2025, BGLC quarterly cash flow from operations is -$1.46 million, with the most recent change of -$789.00 thousand (-117.67%) on September 30, 2024.
- Over the past year, BGLC quarterly CFO has dropped by -$789.00 thousand (-117.67%).
- BGLC quarterly CFO is now -256.51% below its all-time high of $932.50 thousand, reached on December 1, 2020.
Performance
BGLC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$2.43 M
-$560.20 K-30.02%
September 30, 2024
Summary
- As of February 7, 2025, BGLC TTM cash flow from operations is -$2.43 million, with the most recent change of -$560.20 thousand (-30.02%) on September 30, 2024.
- Over the past year, BGLC TTM CFO has dropped by -$560.20 thousand (-30.02%).
- BGLC TTM CFO is now -247.46% below its all-time high of $1.65 million, reached on March 1, 2021.
Performance
BGLC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
BGLC Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -335.9% | -117.7% | -30.0% |
| 3 y3 years | -335.5% | -1152.8% | -612.9% |
| 5 y5 years | -374.9% | -1152.8% | -612.9% |
BGLC Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -335.9% | at low | -402.2% | at low | -476.0% | at low |
| 5 y | 5-year | -335.5% | at low | -256.5% | at low | -247.5% | at low |
| alltime | all time | -335.5% | at low | -256.5% | at low | -247.5% | at low |
BioNexus Gene Lab Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.46 M(+117.7%) | -$2.43 M(+30.0%) |
| Jun 2024 | - | -$670.50 K(+1849.1%) | -$1.87 M(+53.0%) |
| Mar 2024 | - | -$34.40 K(-86.9%) | -$1.22 M(-6.3%) |
| Dec 2023 | -$1.30 M(-335.9%) | -$261.90 K(-70.9%) | -$1.30 M(+131.2%) |
| Sep 2023 | - | -$899.30 K(+3678.6%) | -$562.90 K(-187.2%) |
| Jun 2023 | - | -$23.80 K(-79.6%) | $645.30 K(+36.4%) |
| Mar 2023 | - | -$116.50 K(-124.4%) | $473.10 K(-14.3%) |
| Dec 2022 | $551.80 K(+5897.8%) | $476.70 K(+54.3%) | $551.80 K(-1.1%) |
| Sep 2022 | - | $308.90 K(-257.6%) | $558.10 K(-1.2%) |
| Jun 2022 | - | -$196.00 K(+418.5%) | $565.10 K(-492.4%) |
| Mar 2022 | - | -$37.80 K(-107.8%) | -$144.00 K(-1665.2%) |
| Dec 2021 | $9200.00 | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | $483.00 K(+52.9%) | $9200.00(-98.0%) |
| Sep 2021 | - | $315.90 K(-134.9%) | $458.70 K(-48.9%) |
| Jun 2021 | - | -$905.10 K(-884.3%) | $897.50 K(-45.5%) |
| Mar 2021 | - | $115.40 K(-87.6%) | $1.65 M(+197.7%) |
| Dec 2020 | $552.70 K(-354.3%) | $932.50 K(+23.6%) | $552.70 K(-226.1%) |
| Sep 2020 | - | $754.70 K(-580.1%) | -$438.20 K(-65.0%) |
| Jun 2020 | - | -$157.20 K(-83.9%) | -$1.25 M(+9.1%) |
| Mar 2020 | - | -$977.30 K(+1573.5%) | -$1.15 M(+427.4%) |
| Dec 2019 | -$217.30 K(-20.7%) | -$58.40 K(+1.7%) | -$217.30 K(+36.8%) |
| Sep 2019 | - | -$57.40 K(+8.5%) | -$158.90 K(+56.6%) |
| Jun 2019 | - | -$52.90 K(+8.8%) | -$101.50 K(+108.8%) |
| Mar 2019 | - | -$48.60 K | -$48.60 K |
| Dec 2018 | -$274.10 K | - | - |
FAQ
- What is BioNexus Gene Lab annual cash flow from operations?
- What is the all time high annual CFO for BioNexus Gene Lab?
- What is BioNexus Gene Lab annual CFO year-on-year change?
- What is BioNexus Gene Lab quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioNexus Gene Lab?
- What is BioNexus Gene Lab quarterly CFO year-on-year change?
- What is BioNexus Gene Lab TTM cash flow from operations?
- What is the all time high TTM CFO for BioNexus Gene Lab?
- What is BioNexus Gene Lab TTM CFO year-on-year change?
What is BioNexus Gene Lab annual cash flow from operations?
The current annual CFO of BGLC is -$1.30 M
What is the all time high annual CFO for BioNexus Gene Lab?
BioNexus Gene Lab all-time high annual cash flow from operations is $552.70 K
What is BioNexus Gene Lab annual CFO year-on-year change?
Over the past year, BGLC annual cash flow from operations has changed by -$1.85 M (-335.88%)
What is BioNexus Gene Lab quarterly cash flow from operations?
The current quarterly CFO of BGLC is -$1.46 M
What is the all time high quarterly CFO for BioNexus Gene Lab?
BioNexus Gene Lab all-time high quarterly cash flow from operations is $932.50 K
What is BioNexus Gene Lab quarterly CFO year-on-year change?
Over the past year, BGLC quarterly cash flow from operations has changed by -$789.00 K (-117.67%)
What is BioNexus Gene Lab TTM cash flow from operations?
The current TTM CFO of BGLC is -$2.43 M
What is the all time high TTM CFO for BioNexus Gene Lab?
BioNexus Gene Lab all-time high TTM cash flow from operations is $1.65 M
What is BioNexus Gene Lab TTM CFO year-on-year change?
Over the past year, BGLC TTM cash flow from operations has changed by -$560.20 K (-30.02%)